FPT Digital Retail Joint Stock Company (FRT) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
3 Nov, 2026Executive summary
FY2023 net revenue was VND 31.85tn, while net loss after tax was VND 329.2bn, versus net profit of VND 398.1bn in FY2022.
Total assets reached VND 13.10tn at year-end; current liabilities were VND 11.38tn, including VND 8.11tn of short-term borrowings.
Financial highlights
FY2023 net revenue was VND 31.85tn vs VND 30.17tn; gross profit was VND 5.16tn vs VND 4.70tn.
Operating loss was VND 296.5bn vs operating profit of VND 474.0bn; loss before tax was VND 294.2bn vs profit before tax of VND 485.6bn.
FY net loss attributable to parent shareholders was VND 345.6bn; basic EPS was -VND 2,537 vs VND 2,865 in FY2022.
Q4 net revenue was VND 8.69tn vs VND 8.46tn; Q4 net loss after tax was VND 103.5bn vs net profit of VND 96.7bn.
Segment performance
Operations comprised informatics equipment, mobile phones, components and accessories, and pharmaceutical business; activity was conducted in Vietnam.
FPT Long Chau Pharma held 80.47% ownership and voting interest; Viet Han Friendship, focused on warehouse services, held 99.98%.
Latest events from FPT Digital Retail Joint Stock Company
- Parent-attributable loss and negative operating cash flow marked a weak Q1 despite VND 7.753tn revenue.FRT
Q1 2023 - Revenue grew, but H1 swung to operating and net losses.FRT
Q2 2023 - Revenue grew, but 9M 2023 ended in a VND 225.704bn net loss.FRT
Q3 2023 - Gross profit and operating cash flow improved as revenue fell and losses narrowed.FRT
Q1 2024 - 9M revenue rose and earnings returned to profit, with operating cash flow at VND 1.74T.FRT
Q3 2024 - H1 revenue advanced, earnings returned to profit, and operating cash flow strengthened.FRT
Q2 2024 - FY2024 returned to profit despite lower revenue, with year-end cash rising to VND 1.170tn.FRT
Q4 2024 - Q1 net profit reached VND 212.8bn as revenue climbed to VND 11.67tn.FRT
Q1 2025 - H1 profit more than tripled as revenue advanced and pharmaceutical operations led segment results.FRT
Q2 2025